The FDA recently revised the dosing guidelines for the HIV drug Viramune (nevirapine, a member of the non-nuke class), based on new data. Here’s the news: For infants and children, dosing should be based not on weight but on total body surface area (calculated using height and weight). To minimize the risk of developing a rash or other side effects, people prescribed Viramune should begin by taking a half dose for the first two weeks. Now, people who experience the rash can keep taking the initial half dose even after 14 days—but not for more than 28 (if rash persists at that point, a switch is needed). And anyone with moderate or severe liver problems is now advised to avoid Viramune altogether. Search for “Viramune prescribing information updated” at AIDSmeds.com for details.
October 1, 2008 • By Laura Whitehorn